WallStreetZenWallStreetZen

NASDAQ: BIVI
Biovie Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BIVI stock forecasts and price targets.

Forecast return on equity

Is BIVI forecast to generate an efficient return?

Company
N/A
Industry
31.95%
Market
167.61%

Forecast return on assets

Is BIVI forecast to generate an efficient return on assets?

Company
N/A
Industry
37.36%

BIVI earnings per share forecast

What is BIVI's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.64
Avg 2 year Forecast
-$0.58

BIVI revenue forecast

What is BIVI's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

BIVI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BIVI$1.40N/AN/A
TOVX$0.23$1.00+334.78%Strong Buy
ADIL$3.98$8.50+113.57%Strong Buy
INAB$1.10$6.00+445.45%Buy
ASBP$7.85N/AN/A
View Top Biotech Stocks

Biovie Stock Forecast FAQ

What is BIVI's earnings growth forecast for 2027-2028?

(NASDAQ: BIVI) Biovie's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.63%.

Biovie's earnings in 2026 is -$22,116,407.On average, 3 Wall Street analysts forecast BIVI's earnings for 2027 to be -$4,846,899, with the lowest BIVI earnings forecast at -$4,656,825, and the highest BIVI earnings forecast at -$4,989,455.

In 2028, BIVI is forecast to generate -$4,385,290 in earnings, with the lowest earnings forecast at -$4,213,318 and the highest earnings forecast at -$4,514,269.

If you're new to stock investing, here's how to buy Biovie stock.

What is BIVI's revenue growth forecast for 2028-2030?

(NASDAQ: BIVI) Biovie's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.

Biovie's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast BIVI's revenue for 2028 to be $0, with the lowest BIVI revenue forecast at $0, and the highest BIVI revenue forecast at $0. On average, 3 Wall Street analysts forecast BIVI's revenue for 2029 to be $0, with the lowest BIVI revenue forecast at $0, and the highest BIVI revenue forecast at $0.

In 2030, BIVI is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BIVI's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: BIVI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 37.36%.

What is BIVI's Earnings Per Share (EPS) forecast for 2027-2028?

(NASDAQ: BIVI) Biovie's current Earnings Per Share (EPS) is -$3.05. On average, analysts forecast that BIVI's EPS will be -$0.64 for 2027, with the lowest EPS forecast at -$0.62, and the highest EPS forecast at -$0.66. In 2028, BIVI's EPS is forecast to hit -$0.58 (min: -$0.56, max: -$0.60).

What is BIVI's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: BIVI) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.